Interleukin-13 -1112 C/T promoter polymorphism confers risk for COPD: a meta-analysis.

Chen, Lei; Shen, Yongchun; Liu, Lian; Li, Xiaoou; Wang, Tao; Wen, Fuqiang · PLoS One · 2013

meta_analysis · Level I

Where this comes from

Abstract

Interleukin (IL)-13, a T-helper type 2 cytokine, plays a critical role in the development of chronic obstructive pulmonary disease (COPD). This meta-analysis was performed to assess the association of IL-13 -1112 C/T promoter polymorphism with COPD susceptibility. Published case-control studies from Pubmed and China National Knowledge Infrastructure (CNKI) databases were retrieved. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated. Eight case-control studies in seven articles were included in this meta-analysis. Pooled effect size showed IL-13 -1112 C/T was associated with COPD susceptibility in a codominant genetic model (TT vs CT, OR: 1.82, 95% CI: 1.14-2.92 and TT vs CC, OR: 2.02, 95% CI: 1.10-3.72), indicating individuals with TT genotype had an increased risk for COPD compared with those with CT or CC genotype. According to ethnicity, results indicated IL-13 -1112 C/T was correlated with COPD susceptibility in Arabians (TT vs CT, OR: 2.94, 95% CI: 1.03-8.42 and TT vs CC, OR: 3.05, 95% CI: 1.08-8.59). Moreover, after excluding the study without Hardy-Weinberg equilibrium, the pooled results were robust and no publication bias was found in this study. This meta-analysis suggests IL-13 -1112 C/T promoter polymorphism is associated with the risk of COPD in Arabians.

Medical subject headings